Bliss GVS Pharma Limited has informed the Exchange that the Board has approved the Final Dividend for the FY 2025-2026.
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts more than Nifty Microcap 250 and 1.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Bliss GVS Pharma's Board approved a final dividend of Rs. 1 per equity share (100% on face value of Rs. 1 each) for FY 2025-26, subject to shareholder approval at the 41st AGM on July 15, 2026. The company reported strong full-year results with standalone revenue of Rs. 6,612 crore and net profit of Rs. 324.2 lakh. On consolidated basis, revenue stood at Rs. 8,085.7 crore with net profit of Rs. 966.9 lakh. The auditors issued unmodified opinions on both standalone and consolidated financials. The company also reappointed BDO India as internal auditor for FY 2026-27.
The 100% dividend payout signals management confidence in the company's financial health. For shareholders, this provides immediate cash returns, though the actual yield depends on the prevailing stock price. The strong consolidated profitability demonstrates the benefit of the company's global subsidiary network.